GlassScriptPhysician profile
Chrisselle Kim
NPI 1477336998
$3,362.57
in general payments reported to CMS, 2019-2025
36 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 92% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,665 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772 · Education: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.02 |
| Education | $590.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $443.85 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $272.92 | 2024-2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $259.79 | 2024-2025 | Keytruda |
| Incyte Corporation | $219.71 | 2024-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $215.46 | 2024-2025 | Tagrisso, Calquence, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $181.07 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $170.12 | 2024-2025 | Opdivo, Reblozyl |
| Alexion Pharmaceuticals, INC. | $145.25 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $127.14 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Tempus Ai, INC | $121.20 | 2024-2025 | Xt Cdx |
| Boston Scientific Corporation | $106.81 | 2025 | Watchman Flx |
| Seagen INC. | $98.65 | 2024 | |
| Novartis Pharmaceuticals Corporation | $89.77 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Janssen Biotech, INC. | $83.25 | 2024-2025 | Rybrevant, Tecvayli |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80.23 | 2024-2025 | |
| Genzyme Corporation | $79.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.45 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Stemline Therapeutics INC. | $49.92 | 2025 | Orserdu |
| Emd Serono, INC. | $47.90 | 2024-2025 | |
| Pfizer INC. | $42.96 | 2024 | |
| Genentech USA, INC. | $42.66 | 2024-2025 | Polivy, Tecentriq, Alecensa |
| Aveo Pharmaceuticals, INC. | $36.44 | 2024 | |
| Pharmacosmos Therapeutics INC. | $35.17 | 2024 | Cosela, Monoferric |
| Geron Corporation | $33.68 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.85 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $31.77 | 2025 | Onivyde, Tazverik |
| Pharmaessentia USA Corporation | $25.33 | 2025 | Besremi |
| Exelixis INC. | $22.63 | 2024 | Cabometyx |
| Esteve Pharmaceuticals LLC | $20.10 | 2025 | Metopirone, Lysodren |
| Array Biopharma INC | $17.87 | 2024 | Tukysa, Braftovi |
| Beone Medicines USA, INC. | $17.01 | 2025 | Brukinsa |
| Eisai INC. | $16.89 | 2025 | |
| Legend Biotech USA INC. | $16.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.93 | 2024 | Xarelto |
| Servier Pharmaceuticals LLC | $14.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrisselle Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.